Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 887 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ESTRING Clear all
Completed Phase 3 Interventional

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

NCT00027859
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine phosphate sodium, ketoconazole, therapeutic hydrocortisone
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
98
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 29, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra

NCT00269620
View directory record Official record
Conditions
Contraception
Interventions
ethinyl estradiol/etonogestrel vaginal ring, ethinyl estradiol/norelgestromin transdermal contraceptive
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2008 · Synced Oct 29, 2026, 2:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

VEDA Study (DHEA vs Estradiol)

NCT07574216
View directory record Official record
Conditions
Post-menopause, Pre-menopause, Sexual Function, Menopause, Vaginal Dryness, Painful Intercourse
Interventions
DHEA ovals, Estradiol 0.01% Vag Cream
Drug
Lead sponsor
University of Arizona
Other
Eligibility
40 Years to 90 Years · Female only
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 29, 2026, 2:42 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Endometriosis and Migraine

NCT06785129
View directory record Official record
Conditions
Migraine, Endometriosis
Interventions
Thermal stimuli, Pressure stimuli, Pain ratings, Conditioned pain modulation (CPM) response, Hormonal assessment
Device · Behavioral · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 29, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Blood Flow Responses to Stress: Sex Differences

NCT06253702
View directory record Official record
Conditions
Cerebrovascular Disorders
Interventions
Indomethacin, Placebo, Orilissa, Testosterone gel, Anastrozole, Estradiol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 29, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .

NCT01077505
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, Oral contraceptive (Brevicon)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 29, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System

NCT00650442
View directory record Official record
Conditions
Healthy
Interventions
Estradiol Transdermal System Placebo - Alternate Adhesive, Estradiol Transdermal System Placebo - Current Adhesive
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years to 66 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 29, 2026, 2:42 AM EDT
Withdrawn Phase 4 Interventional

Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients

NCT00826839
View directory record Official record
Conditions
Infertility
Interventions
Oral contraceptive pill and microdose lupron, E2 patch/antagonist
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 29, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

NCT01597193
View directory record Official record
Conditions
Breast Cancer
Interventions
enzalutamide, anastrozole, exemestane, fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
17
States / cities
Aurora, Colorado • Enfield, Connecticut • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 29, 2026, 2:42 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

NCT05251714
View directory record Official record
Conditions
Advanced Solid Tumor, Breast Cancer
Interventions
CFI-402257, Fulvestrant
Drug
Lead sponsor
Treadwell Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Columbus, Ohio • San Antonio, Texas • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 29, 2026, 2:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Palbociclib After CDK and Endocrine Therapy (PACE)

NCT03147287
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib, Fulvestrant, Avelumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
22
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 29, 2026, 2:42 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

NCT05221021
View directory record Official record
Conditions
Overactive Bladder Syndrome
Interventions
Vaginal estrogen, Mirabegron 50 MG [Myrbetriq]
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 29, 2026, 2:42 AM EDT
Active, not recruiting Phase 3 Interventional

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT06016738
View directory record Official record
Conditions
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions
Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane
Drug
Lead sponsor
Olema Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
47
States / cities
Tucson, Arizona • Fountain Valley, California • Glendale, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 29, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer

NCT02632045
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Carcinoma
Interventions
LEE-011, Fulvestrant, Placebo
Drug
Lead sponsor
Melissa K Accordino
Other
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 29, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

NCT06820307
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine, DRSP/EE, NGM/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 29, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

NCT03584009
View directory record Official record
Conditions
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Interventions
Venetoclax, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 29, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

Preventing Recurrent UTI With Vaginal Estrogen

NCT05551949
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Urinary Tract Infections, Cystitis Recurrent
Interventions
Vaginal estradiol tablets
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
55 Years to 100 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 29, 2026, 2:42 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)

NCT00481455
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
Panzem NCD, Temozolomide
Drug
Lead sponsor
CASI pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2008 · Synced Oct 29, 2026, 2:42 AM EDT
Completed Phase 3 Interventional

Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms

NCT00108849
View directory record Official record
Conditions
Menopause, Postmenopausal Vaginal Atrophy
Interventions
estradiol, 10 mcg
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
51
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 29, 2026, 2:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT04579380
View directory record Official record
Conditions
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
Interventions
tucatinib, trastuzumab, fulvestrant
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
76
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 29, 2026, 2:42 AM EDT
Completed Phase 3 Interventional

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

NCT00238732
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 29, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

NCT00570921
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Fulvestrant
Drug
Lead sponsor
Mara Chambers
Other
Eligibility
45 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 29, 2026, 2:42 AM EDT
Withdrawn Phase 2 Interventional

Fulvestrant + Neratinib In Breast Cancer

NCT04901299
View directory record Official record
Conditions
Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer, HER2-negative Breast Cancer, Invasive Breast Cancer
Interventions
NERATINIB, FULVESTRANT
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 29, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

NCT03213457
View directory record Official record
Conditions
Endometriosis
Interventions
Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix, Placebo for E2/NETA
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
188
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 29, 2026, 2:42 AM EDT